Respiratory failure & ventilation
Extracorporeal Carbon Dioxide Removal to De-escalate Venovenous Extracorporeal Membrane Oxygenation in Severe COVID-19 Acute Respiratory Distress Syndrome
Authors' conclusion
Extracorporeal carbon dioxide removal can be used to continue supportive methods for patients with refractory type 2 hypercarbic respiratory failure after COVID-19 ARDS for patients previously on VV ECMO. Patients with low compliance have a higher rate of reescalation to VV ECMO.
Study context
- Population
- Patients with refractory hypercarbic respiratory failure after COVID-19 acute respiratory distress syndrome (ARDS) previously supported with VV extracorporeal membrane oxygenation (ECMO)
- Participants
- 21 patients
- Outcome
- Outcome of transition from VV ECMO to ECCO2R
Methodological detailssingle-centre, quaternary-care academic medical center
- Single-centre
- Quaternary-care academic medical center
Main finding
As reported in the abstract
Successfully transitioned to ECCO2R and decannulated
17
Re-escalated to VV ECMO for hypercapnic respiratory failure
3
Died on ECCO2R
1
Observational data: associations, not effects.
Further findings
Low compliance (<20 mL/cmH2O) at transition (subgroup)
- Transitioned to ECCO2R with compliance <20 mL/cmH2O
- Five (23.8%) of the 21
- Low-compliance patients re-escalated to VV ECMO
- 3
Original publication
Extracorporeal Carbon Dioxide Removal to De-escalate Venovenous Extracorporeal Membrane Oxygenation in Severe COVID-19 Acute Respiratory Distress Syndrome. J Cardiothorac Vasc Anesth. Published 21 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →